ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Options Flow

Live Options Flow

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
S&P TSX Capped Composite...
40.62
-0.37%
US Tech 100
20,874.00
-1.46%
S&P 500
6,025.99
-0.95%
US Dollar vs CAD
1.434
0.30%
Bitcoin
96,914.46
0.44%
Registration Strip Icon for tools Level up your trading with our powerful tools and real-time insights all in one place.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Revance Therapeutics Inc (RVNC) Share Price

Revance Therapeutics Inc

Revance Therapeutics Inc (RVNC)

NASDAQ
3.65
0.00
(0.00%)
Closed February 09 3:00PM
Delayed by 15 minutes
0.00
0.00
(0.00%)
After Hours: -
Delayed by 15 minutes

Empower your portfolio: Real-time discussions and actionable trading ideas.

Premium

Key stats and details

Current Price
3.65
Bid
3.84
Ask
3.10
Volume
-
0.00 Day's Range 0.00
2.30 52 Week Range 7.56
Market Cap
382.894M
Previous Close
3.65
Open
-
Last Trade
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
2,915,551
Shares Outstanding
104,902,388
Dividend Yield
-
PE Ratio
-1.18
Earnings Per Share (EPS)
-3.09
Revenue
234.04M
Net Profit
-323.99M

About Revance Therapeutics Inc

Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD pl... Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are Product and the Service Segment. The Products segment generates maximum revenue which is engaged in the research and development of aesthetic and therapeutic products. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.revance.com
Headquarters
Wilmington, Delaware, USA
Founded
-
Revance Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker RVNC. The last closing price for Revance Therapeutics was US$3.65. Over the last year, Revance Therapeutics shares have traded in a share price range of US$ 2.30 to US$ 7.56.

Revance Therapeutics currently has 104,902,388 shares outstanding. The market capitalization of Revance Therapeutics is US$382.89 million. Revance Therapeutics has a price to earnings ratio (PE ratio) of -1.18.

Ask ADVFN Intelligence (AI)

RVNC Latest News

More News

Crown Laboratories Completes Acquisition of Revance Therapeutics

Yesterday, Crown Laboratories, Inc. ("Crown"), a Hildred Capital portfolio company and privately held, global innovative leader in the skincare industry, announced the closing of its acquisition...

February 07 2025
Business Wire

Form 4 - Statement of changes in beneficial ownership of securities

February 06 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 06 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 06 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 06 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 06 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 06 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 06 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 06 2025
Edgar (US Regulatory)

Form 4 - Statement of changes in beneficial ownership of securities

February 06 2025
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10.010.2747252747253.643.663.6221006313.63906316CS
40.339.939759036143.323.73.2328809153.58818477CS
12-0.56-13.30166270784.214.2253.0129155513.39634722CS
260.4714.77987421383.186.652.838569585.11224801CS
52-2.25-38.13559322035.97.562.328848514.77927004CS
156-9.69-72.638680659713.3437.982.3185386812.18429626CS
260-22.51-86.047400611626.1637.982.3136729014.11008619CS

RVNC - Frequently Asked Questions (FAQ)

What is the current Revance Therapeutics share price?
The current share price of Revance Therapeutics is US$ 3.65
How many Revance Therapeutics shares are in issue?
Revance Therapeutics has 104,902,388 shares in issue
What is the market cap of Revance Therapeutics?
The market capitalisation of Revance Therapeutics is USD 382.89M
What is the 1 year trading range for Revance Therapeutics share price?
Revance Therapeutics has traded in the range of US$ 2.30 to US$ 7.56 during the past year
What is the PE ratio of Revance Therapeutics?
The price to earnings ratio of Revance Therapeutics is -1.18
What is the cash to sales ratio of Revance Therapeutics?
The cash to sales ratio of Revance Therapeutics is 1.64
What is the reporting currency for Revance Therapeutics?
Revance Therapeutics reports financial results in USD
What is the latest annual turnover for Revance Therapeutics?
The latest annual turnover of Revance Therapeutics is USD 234.04M
What is the latest annual profit for Revance Therapeutics?
The latest annual profit of Revance Therapeutics is USD -323.99M
What is the registered address of Revance Therapeutics?
The registered address for Revance Therapeutics is 1209 ORANGE STREET, WILMINGTON, DELAWARE, 19801
What is the Revance Therapeutics website address?
The website address for Revance Therapeutics is www.revance.com
Which industry sector does Revance Therapeutics operate in?
Revance Therapeutics operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
MGOLMGO Global Inc
US$ 0.4191
(126.54%)
816.59M
CDTConduit Pharmaceuticals Inc
US$ 2.831
(82.65%)
144.17M
GSIWGarden Stage Ltd
US$ 0.79
(78.73%)
219.64M
TOIIWOncology Institute Inc
US$ 0.033
(58.88%)
7.27k
CYTHCyclo Therapeutics Inc
US$ 1.19
(54.55%)
84.73M
FTELFitell Corporation
US$ 2.70
(-57.01%)
2.3M
SGBXSafe and Green Holdings Corporation
US$ 0.6401
(-44.82%)
5.65M
NKLANikola Corporation
US$ 0.4432
(-41.10%)
52.44M
PLRXPliant Therapeutics Inc
US$ 7.785
(-34.85%)
6.44M
LIPOLipella Pharmaceuticals Inc
US$ 3.08
(-33.76%)
2.2M
MGOLMGO Global Inc
US$ 0.4191
(126.54%)
816.59M
RIMEAlgorhythm Holdings Inc
US$ 0.0169
(-20.66%)
274.2M
NVDANVIDIA Corporation
US$ 129.84
(0.90%)
228.2M
GSIWGarden Stage Ltd
US$ 0.79
(78.73%)
219.64M
BHATBlue Hat Interactive Entertainment Technology
US$ 0.0537
(14.74%)
212.29M

RVNC Discussion

View Posts
vinmantoo vinmantoo 2 days ago
If only we could be as wise as CosmeticMD, the king of gracious posting.

You mean the proven liar who whined people didn't trust a liar.
👍️ 1
Ellington Ellington 2 days ago
If only we could be as wise as CosmeticMD, the king of gracious posting.
👍️0
PioneerUniverse8 PioneerUniverse8 2 days ago
reading some of my old posts... Boy was I wrong.
👍️0
CosmeticMD CosmeticMD 3 days ago
And this is what happens to ignorami who ignore actual real world experience. Enjoy your $3.65 a share (which is about 1/10 what I sold my Revance Shares for)
👍️0
CosmeticMD CosmeticMD 3 days ago
Naw, seeing patients all day, busier than ever. But good luck in the future. Maybe listen to those who actually use the product instead of some guy that bases his entire investment philosophy on a single study.
👍️ 1
alertmeipp alertmeipp 3 days ago
Goodbye, everyone—wishing you all the best in your future investments!
👍️ 4
vinmantoo vinmantoo 3 days ago
I'm sorry you lost your license to practice medicine..

That is what happens to an "MD" who lies and pretends. I didn't bother reading the comment of that proven liar.
👍️0
biotech_researcher biotech_researcher 4 days ago
I'm sorry you lost your license to practice medicine.. Good luck to you..
👍️ 1
alertmeipp alertmeipp 4 days ago
Had really high hope for the product, thought the turnaround would gain the traction and worst case would be a sale, but with higher price.

Management either corrupted or sucks
👍️ 1
CosmeticMD CosmeticMD 4 days ago
I'll miss all of you. Especially the ones who told me I was wrong when I said this was a crap product and a crap company a year and a half ago...
👍️ 2
YY1000 YY1000 4 days ago
FYI, I sold all my RVNC shares in a Fidelity Roth account at 3:57pm with a 3.65 limit (so I wouldn't have to worry about this account getting paid) and the order was filled at 3.66! Size was higher than a similar order for 50,000 shares on Schwab that was filled at 3.65. That is significantly better execution on Fidelity! The highest price I see in trades around this time is 3.655, so almost looks like Fidelity ate a couple hundred dollars on this transaction. Strange...

Now have to wait and see how long it takes until my remaining shares get paid.
👍️0
YY1000 YY1000 4 days ago
Answering my question here... there is a 0.0002674 exchange fee per share on the sale, so unless one gets at least 3.6503 execution, it is better to wait until closing tomorrow. As a retail investor I cannot specify a fractional cent limit.

I wonder if buyers that are paying 2.655 today (also there have been some trades at 2.66) could be shorts covering or closing other hedges, who if they had waited until tomorrow might have faced fees higher than 0.005 per share to close their positions.
👍️ 1
Ellington Ellington 4 days ago
And why is someone paying more than $3.65?

I sold all today.
👍️0
YY1000 YY1000 4 days ago
I don't know about biggest, but certainly my costliest investing mistake...
Any reason not to sell today? I have not tendered any shares and this way I get the money a day early...
Updating the previous version of this message, on 1000 share trades Schwab gives me 3.6505, but on 50,000 shares I got 3.6500, so I don't see a way to get a better price, even though several trades go through at 3.655...
👍️0
vinmantoo vinmantoo 4 days ago
RVNC was my biggest investing mistake ever. Daxxify is a great product, but management undercut the company's prospects again and again. C'est la vie.

Dew, I sold the rest of my RVNC shares on Monday. I didn't want to open my Schwab account and see RVNC listed among my holdings, even though it just advanced that outcome by a few days. Better luck next for both of us on our other investments.
👍️0
valiano valiano 4 days ago
Thanks for posting your thoughts all along, Dew. I'm sure you'll bounce back :)
👍️ 1
Ellington Ellington 5 days ago
Why is the bid-ask at 3.65-3.66, with more at the bid?
👍️0
DewDiligence DewDiligence 5 days ago
Crown-RVNC merger will close tomorrow (2/6/25):

https://www.sec.gov/Archives/edgar/data/1479290/000119312525020472/d814461dsc14d9a.htm

82% of RVNC shares tendered, exceeding the 50% threshold for completing the deal.

RVNC was my biggest investing mistake ever. Daxxify is a great product, but management undercut the company's prospects again and again. C'est la vie.
👍️ 8
Emannow Emannow 1 week ago
Allergan continues to lose market share in both toxin and filler!

Sadly, Foley blew all the RVNC’s cash with his terrible decisions and destroyed the company! Now Bill Meury from Crown Labs told me years ago, that Foley was a terrible person and idiot! Bill was right!!!

Global net revenues from the aesthetics portfolio were $1.298 billion, a decrease of 5.2 percent on a reported basis, or 4.4 percent on an operational basis.
Global Botox Cosmetic net revenues were $687 million, a decrease of 4.2 percent on a reported basis, or 3.4 percent on an operational basis.
Global Juvederm net revenues were $279 million, a decrease of 16.3 percent on a reported basis, or 15.1 percent on an operational basis.
👍️ 4
IanFromSI IanFromSI 1 week ago
If the deal is terminated without Crown Labs buying RVNC, then those who have not yet sold their shares will get whatever the market offers.

Worst case, given that Revance management has issued multiple going concern warnings, those still holding the shares may end up with zero dollars to show for it.

If crown labs gets at least 50% of the shares (plus one share), then it can force any remaining holders of its shares to sell at the tender price
👍️ 1
DewDiligence DewDiligence 1 week ago
If the deal goes through, shareholders who don't tender get the same payout as those who do tender, but it may take slightly longer to get paid.
👍️ 2
Ellington Ellington 1 week ago
I wonder if that's the end of the game.

There was something in the SEC document about a two-step process, such that people not tendering could conceivably lose out if the second step didn't happen.
👍️0
DewDiligence DewDiligence 2 weeks ago
Teoxane throws in the towel—will tender shares to Crown:

https://www.sec.gov/Archives/edgar/data/1479290/000095010325001086/xslSCHEDULE_13D_X01/primary_doc.xml

Teoxane was bluffing about wanting to acquire RVNC, IMO, but the bluff succeeded in getting Crown to pay an additional $0.55/sh.
👍️ 1
MrMILL MrMILL 3 weeks ago
What does that even mean?  If I'm not mistaken, we are done here with them accepting Crowns deal at $3.65?  I was hoping that TEOXANE would counter it back at $4.00 and Crown would walk.  Foley is definitely in bed with Crown.
👍️0
alertmeipp alertmeipp 3 weeks ago
the buyout deal is terminated.

Maybe a bit selfish here, but that would be a nice outcome and I would happily buy back my shares if that happens.
👍️ 1
DewDiligence DewDiligence 3 weeks ago
RVNC accepts Crown’s $3.65/sh—tender_must_be_completed_by 2/7/25:

https://investors.revance.com/investors/Press-Releases/news-details/2025/Crown-Laboratories-and-Revance-Amend-the-AR-Merger-Agreement-to-Increase-Offer-Price-to-3.65-per-Share-and-Extend-Existing-Tender-Offer/default.aspx

If Crown does not obtain a majority of RVNC shares by 2/7/25, the buyout deal is terminated.
👍️0
stocksrising stocksrising 3 weeks ago
better than most of us who sold ALL ( some at $6.51 and $3.07ish).. only some friends and fam didn't sell/tender yet.. Crown not giving bod much time to decide, shotgun wedding it seems :)....will be interesting* if Teox comes back today with any filings( Sec, or RVNC) with higher bid, or at this point, who knows?????
actually don't care anymore with this drama show, just focusing on 3 other potential 5/10 baggers in 2025...
* for existing SH's
👍️ 1
vinmantoo vinmantoo 3 weeks ago
The Crown Proposal remains subject to formal consent and approval from both Crown’s Board of Directors and Revance’s Board. Crown indicated that the $3.65 offer expires at 4:10 p.m., Eastern Time, on January 17, 2025. The Revance Board will evaluate the Crown Proposal consistent with its duties.

The scumbags at Crown are giving RVNC only ONE day to consent. Come on Teoxane, beat that offer.
🤣 1
vinmantoo vinmantoo 3 weeks ago
$3.65 is my guess, lmao …today!!

You can thank me for the price rise as I sold half my remaining shares yesterday just before close.
👍️0
whoswho whoswho 3 weeks ago
Item 8. Additional Information to be Furnished.

Item 8 (“Additional Information”) of the Schedule 14D-9 is hereby amended and supplemented by adding the following information set forth below after the last paragraph of the subsection entitled “Subsequent Events”:

On January 16, 2025, Crown provided to Revance non-binding proposed amendments to the A&R Merger Agreement, Equity Commitment Letter and Limited Guarantee (together, the “Crown Proposal”). The Crown Proposal contemplates the following material changes to the terms of the A&R Merger Agreement: (i) an increase in the Offer Price to $3.65 per share; (ii) an increase in the Company Termination Fee to $15,290,488.66; and (iii) an increase in the Parent Termination Fee to $22,935,732.99. The Crown Proposal remains subject to formal consent and approval from both Crown’s Board of Directors and Revance’s Board. Crown indicated that the $3.65 offer expires at 4:10 p.m., Eastern Time, on January 17, 2025. The Revance Board will evaluate the Crown Proposal consistent with its duties.
👍️0
whoswho whoswho 3 weeks ago
Thanks for the info!

so now the race is between $3.60 vs $3.65. LOL
👍️0
anesthesia doc anesthesia doc 3 weeks ago
Crown raised their offer to $3.65
👍️0
whoswho whoswho 3 weeks ago
Any news today? why the sudden jump to $3.60+?
👍️0
stocksrising stocksrising 3 weeks ago
$3.65 is my guess, lmao …today!!
😀 2
MrMILL MrMILL 4 weeks ago
Do you or anyone else have an opinion on the latest extension?  Also, the number of shares tendered by shareholders appears very low, or am I not understanding the amount they need?  I for one am holding my shares.  I figure the worst case scenario is $3.10....
👍️0
MeteoricChimera43 MeteoricChimera43 1 month ago
Pomerantz’s Law http://www.pomlaw.com/

They are the first and only Law firm to have already filed an actual case against RVNC and will likely be the lead in a Class Action. You don’t need to still have shares. As long as you owned shares sometime from February 2024 to December 6th, you qualify
👍️ 1
stocksrising stocksrising 1 month ago
Did you go with Josh? {Fruchter}..if so, I started to send docs but decided to just take the hit and move on ...good luck, we will all "win" something ( pennies perhaps) but will get more satisfaction for Fooley & Crew's loss !! GLTA
👍️0
MeteoricChimera43 MeteoricChimera43 1 month ago
Read the new 8k today from Revance talking about considering Teoxane
proposal and Crowns letter to Revance basically acting like “take our offer or we will back out”. How Teoxanes offer isn’t vetted, with no proof that their financing is all committed, therefore not even a valid offer. Basically telling.Revance that they’re not gonna budge and they’re not gonna extend their tender offer termination for next week. I think we all know they’re full of shit and still want the deal and will easily pay 4 to 5 dollars a share to get it. It’ll be interesting to see how long this battle takes, and who comes out on top. Myself and two of my good friends who are large holders of RVNC we’re just named as lead, plaintiffs through one of the biggest law firms and the first firm to file actual suit against Revance last week
👍️ 3
MeteoricChimera43 MeteoricChimera43 1 month ago
What are your guesses about how much Crown will raise their offer price to and when?
👍️0
biotech_researcher biotech_researcher 1 month ago
With the negative response by the market, the arbs are not engaged..
👍️0
Tal10 Tal10 1 month ago
Let the lawsuits against Teoxane begin! This has corruption written all over it.
👍️0
soma2022 soma2022 1 month ago
I feel that Bill Meury (Chair of Crown and Hildred Capital Senior Adviser) will not want over 1 year of hard work and expense to slip away at just a $0.50/share higher price = $52M.

Background of Bill Meury: https://www.hildred.com/team/bill-meury
Allergan's Chief Commercial Officer from 2015 to 2020. Bill was with Actavis in 2014 and was instrumental along with Brent Saunders in blocking Valeant's hostile takeover of Allergan. Actavis then took on the Allergan name and was eventually acquired by Abbvie in 2019.
https://www.reuters.com/article/business/allergan-agrees-to-66-billion-actavis-offer-valeant-walks-idUSKCN0J00W7/

There are indications that Allergan looked at potentially acquiring Revance some 8 to 10 years ago. If these rumors are true, then Bill Meury would have been actively involved in those discussions. If this is the case, then Bill has been patiently stalking Revance waiting for an opportunity like this for almost 10 years.

There is a reasonably strong possibility that Crown will increase their offer price.
👍️ 3 💯 1
stocksrising stocksrising 1 month ago
this offer wasn't shocking to me, anyway.. but needed the funds and loss to build positions in 3 other Bio's... good on you for still in game, we shall see how this drama plays out over coming days.. I think Anus( ANGUS, SORRY Still pissed about b.o.d's) is focused on Structure Thera and can give 2 sh*ts about shareholders :(
still, GLTA that own
👍️ 1
soma2022 soma2022 1 month ago
Termination Fee. Revance may be required to pay the $13,373,000 termination fee to Crown if the A&R Merger Agreement is terminated under certain circumstances, including by Revance to accept a Superior Proposal. The Revance Board considered the risk that the amount of the termination fee would deter potential alternative acquisition proposals.
👍️0
vinmantoo vinmantoo 1 month ago
Teoxane SA Announces Superior Proposal to Acquire Revance
Therapeutics for $3.60 per Share in
Cash
09:03 : Monday 6 January 2025

I still have ~ 1/3 of my shares only because they were the ones not underwater and I was generating tax loss for 2024. I just never got around to the selling the rest as we entered 2025. While I am glad of a higher offer, it would take a counter offer to lessen my annoyance a bit. From the outside it looked like Teoxane torpedoed the $6.66 price so I need Crown or some other entity to start a bidding war.
👍️0
MeteoricChimera43 MeteoricChimera43 1 month ago
Do we think Crown will bid higher? Does Crown already have the 60% threshold of shares to force their buyout and thus is just Texoxane trying to get a higher sale price for their 8% stake
👍️0
stocksrising stocksrising 1 month ago
Teoxane SA Announces Superior Proposal to Acquire Revance
Therapeutics for $3.60 per Share in
Cash
09:03 : Monday 6 January 2025

https://ih.advfn.com/p.php?pid=nmona&article=95199461&_gl=1*k8vpjc*_gcl_au*MjEwMzA0NjM5Ni4xNzM0Mjc3ODAz
👍️ 5
MeteoricChimera43 MeteoricChimera43 1 month ago
Myself and 7 investors I know, are all signed up for the class action suit. We’ll see if they follow through.
👍️ 2 🤣 1
Jab44 Jab44 1 month ago
Reading the 8k reminds me of the last four years of the Foley shit show. It reads like a novel where something nefarious has taken place and it leaves you asking why you didn’t figure it out sooner. Foley is doing his best to cut a deal to maximize his return and the shareholders be damm. In terms of the negotiations it was Foley who did it all and then took it back to the board to try and sell it to them . Receiving 100% of the 2024 bonus along with the golden parachute should be criminal. Who set the goals for 2024? Did Angus Russell even look at them ? Foley gives a number of reasons why he doesn’t feel the company as a standalone is not viable any longer.
Foley should be crucified for what he did to this company and all the shareholders he misled. I sincerely hope this drags out for years !!!
👍️ 8
MrMILL MrMILL 1 month ago
I'm not sure I understand.  Can you explain what you think is happening?
👍️0

Your Recent History

NASDAQ
RVNC
Revance Therapeutics
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Canada
Company
Business
Popular
Get The App
App Store
Google Play

Support: +44 (0) 203 8794 460 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2025 ADVFN PLC - All Rights Reserved

Go Ad-Free

Subscribe to Ad free and enjoy an ad-free experience

No Ads

Try Now

Keep the Ads